Navigation Links
Drug commonly used to treat bipolar disorder dramatically increases lifespan in worms
Date:10/30/2007

Nematode worms treated with lithium show a 46 percent increase in lifespan, raising the tantalizing question of whether humans taking the mood affecting drug are also taking an anti-aging medication. Results of the Buck Institute study, led by faculty member Gordon J. Lithgow, PhD, are currently published online in the Journal of Biological Chemistry.

Lithium has been used to treat mood affective disorders, including bipolar disease for decades. While the drug has been shown to protect neurons, the underlying mechanism of its therapeutic action is not understood. In humans, lithiums therapeutic range is very limited and the drug has serious side effects. The research provides a novel genetic approach to understanding how lithium works and highlights the utility of using the nematode C. elegans as a research subject in the field of pharmacogenetics. Pharmocogenetics involves the study of genetic factors that influence an organisms reaction to a drug.

In the study, scientists discovered that longevity was increased in the worms when the lithium turned down the activity of a gene that modulates the basic structure of chromosomes.

Lithgow believes that lithium impacts many genes. Understanding the genetic impact of lithium may allow us to engineer a therapy that has the same lifespan extending benefits, said Lithgow. One of the larger questions is whether the lifespan extending benefits of the drug are directly related to the fact that lithium protects neurons. The process of normal aging in humans is intrinsically linked to the onset of neurodegenerative disease. However, the cellular changes and events due to aging that impact neurodegeneration are not yet understood said Lithgow. Studies involving compounds such as lithium could provide breakthroughs in the attempt to understand the biomedical link between aging and disease. Lithgow and his lab are now surveying tens of thousands of compounds for affects on aging.

The study highlights the efficacy of using C. elegans as a new way of studying drug toxicity and genetic impacts of compounds currently in drug development or already in use in humans. The use of simple model organisms with well developed genetic tools can speed the identification of molecular targets, said Lithgow. This could facilitate the development of improved therapies for diseases.


'/>"/>

Contact: Kris Rebillot
krebillot@buckinstitute.org
415-209-2260
Buck Institute for Age Research
Source:Eurekalert

Related biology news :

1. Harmful Bacterium Commonly Found in Poultry May Survive Refrigeration and Frozen Storage Combined
2. Ibruprofen and other commonly used painkillers for treating inflammation may increase the risk of heart attack
3. Commonly used antidepressants may also affect human immune system
4. Protein discovery could unlock the secret to better TB treatment
5. Topical treatment shown to inhibit HIV and herpes simplex virus infection
6. Antarctic ice shelf retreats happened before
7. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
8. Researchers add new tool to tumor-treatment arsenal
9. Discovery Could Lead To Novel Approaches In HIV Treatment
10. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
11. FDA Approves New Drug to Treat Type I and Type II Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)... MINNETONKA, Minn. , Feb. 7, 2017   ... that supports the entire spectrum of clinical research, is ... iMedNet , its innovative, highly flexible and ... iMedNet customers. iMedNet is a ... only provides Electronic Data Capture (EDC), but also delivers ...
(Date:2/6/2017)... 6, 2017 According to Acuity Market ... border authorities to continue to embrace biometric and ... 2143 Automated Border Control (ABC) eGates and 1436 ... more than 163 ports of entry across the ... achieving a combined CAGR of 37%. APC Kiosks ...
(Date:2/2/2017)... Fla. , Feb. 2, 2017   ... a clinical-stage immuno-oncology company specializing in the development ... for the treatment of cancer and metastatic disease, ... scale-up and GMP manufacturing of a second clinical ... vaccine targeting folate receptor alpha. The manufactured vaccine ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... 2017  Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics ... biopharmaceutical products for companion animals, will host a live conference ... to discuss financial results from the fourth quarter and full ... and investors may access the audio webcast or ... ...
(Date:2/22/2017)... , Feb. 22, 2017 Scientists propose ... inflammation and organ damage in Gaucher and maybe other ... risks and lower costs than current therapies. ... Hospital Medical Center , which also included investigators from ... , report their data Feb. 22. The study was ...
(Date:2/22/2017)... ... February 22, 2017 , ... LabRoots , the ... from around the world, is pleased to announce the launch of a new scholarship ... mathematics (STEM) fields. , This merit-based scholarship is open to all high school seniors, ...
(Date:2/22/2017)... ... February 22, 2017 , ... NDA Partners Chairman Carl ... Deputy Director in the FDA CDRH Division of Cardiovascular, Respiratory, and Neurological Devices ... as an Expert Consultant. , In Dr. Spyker’s accomplished career, he held positions ...
Breaking Biology Technology: